Patients often come into my office to be “tested for ADHD,” and I explain to them that the diagnosis depends on a thorough clinical interview. Nonetheless, rating scales can be useful.
Read More
In 2006, an FDA panel recommended all manufacturers of stimulants to add a “black box” warning about an increased risk of “serious cardiovascular events.”
Read More
To begin with, you have to specify whether you are thinking in terms of DSM-IV criteria or probable DSM-5 criteria. The major difference is that currently you have to establish that ADHD symptoms began before age seven, whereas DSM-5 is more lenient, requiring that they began by age 12.
Read More
We know that the postpartum period is a risky time for women who have a history of depression, especially if they experienced postpartum depression in the past. But several questions about mood and pregnancy are still unanswered.
Read More
It has been over a year now since the approval of vilazodone (Viibryd). As you may recall from our review of the drug in TCPR April 2011, vilazodone is an SSRI with partial agonism at the 5HT1A receptor.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
